Sustained-release dexamethasone insert shows promise in pediatric cataract surgery
Dextenza, a sustained-release dexamethasone insert, is an effective and convenient option for reducing postoperative inflammation in pediatric intraocular surgery, minimizing the need for frequent eye drops and improving treatment compliance, according to a paper presented at the 50th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus.
The study included 97 pediatric eyes undergoing intraocular procedures, including cataract surgery (n = 68), secondary intraocular lens (IOL) implantation (n = 27), and secondary membrane removal (n = 2). Among cataract surgery patients, 39.4% had no inflammation at 1–2 weeks, increasing to 76.5% at 1 month. In the secondary IOL group, these rates were 53.8% and 91.7%, respectively. Rescue anti-inflammatory drops were needed in about 22% of cases. The only reported complication was the premature loss of the insert in 1 patient.
The findings suggest that Dextenza provides a reliable and convenient alternative for reducing postoperative inflammation in children.
Reference
Morales-Mancillas N, et al. A Sustained Release Intracanalicular Dexamethasone Insert for the Treatment of Ocular Inflammation after Pediatric Intraocular Surgery Across All Age Groups. Presented at: 50th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus; March 5-9, 2025; Salt Lake City, UT.
Related Content
